Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Ahmad Bin Salam"'
Autor:
Anghesom Ghebremedhin, Ahmad Bin Salam, Benjamin Adu-Addai, Steve Noonan, Richard Stratton, Md Shakir Uddin Ahmed, Chandra Khantwal, George R. Martin, Huixian Lin, Chris Andrews, Balasubramanyam Karanam, Udo Rudloff, Henry Lopez, Jesse Jaynes, Clayton Yates
Publikováno v:
Cells, Vol 12, Iss 9, p 1254 (2023)
Activated M2-polarized macrophages are drivers of pulmonary fibrosis in several clinical scenarios, including Idiopathic Pulmonary Fibrosis (IPF). In this study, we investigated the effects of targeting the CD206 receptor in M2-like macrophages with
Externí odkaz:
https://doaj.org/article/634b487e00244c5a87f649e520e2e17c
Autor:
Ravi K Anchoori, Logan George, Ssu-Hsueh Tseng, Brandon Lam, Srinidhi Polkampally, Anjali D Amiano, Palmer Foran, Hannah Tsingine, Harideep Samanapally, Fernanda Carrizo Velasquez, Samarjit Das, Deyin Xing, Ahmad Bin Salam, Balasubramanyam Karanam, Chien-Fu Hung, Richard B S Roden
Publikováno v:
PLoS ONE, Vol 16, Iss 9, p e0256937 (2021)
Bortezomib and the other licensed 20S proteasome inhibitors show robust activity against liquid tumors like multiple myeloma, but have disappointed against solid tumors including ovarian cancer. Consequently, interest is mounting in alternative non-p
Externí odkaz:
https://doaj.org/article/a191fb5eadb24586b1e67b55b0cdb07d
Autor:
Shyam M. Kavuri, Matthew J. Ellis, Bora Lim, Meenakshi Anurag, Balasubramanyam Karanam, Carolina Gutierrez, Clayton C. Yates, Christina Sallas, Alaina Lewis, Lacey E. Dobrolecki, Ahmad Bin Salam, Junkai Wang, Ching Hui Chen, Rashi Kalra
The pan-HER tyrosine kinase inhibitor (TKI) neratinib is therapeutically active against metastatic breast cancers harboring activating HER2 mutations, but responses are variable and often not durable. Here we demonstrate that recurrent HER2 mutations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c34dfb17c7d56237e4e63f40d932b81f
https://doi.org/10.1158/0008-5472.c.6514088.v1
https://doi.org/10.1158/0008-5472.c.6514088.v1
Autor:
Shyam M. Kavuri, Matthew J. Ellis, Bora Lim, Meenakshi Anurag, Balasubramanyam Karanam, Carolina Gutierrez, Clayton C. Yates, Christina Sallas, Alaina Lewis, Lacey E. Dobrolecki, Ahmad Bin Salam, Junkai Wang, Ching Hui Chen, Rashi Kalra
Supplementary Data from Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04aa1a9f176a50d82e6165bcc1ca00a8
https://doi.org/10.1158/0008-5472.22432226
https://doi.org/10.1158/0008-5472.22432226
Autor:
Shyam. M Kavuri, Rashi Kalra, Ching Hui Chen, Junkai Wang, Ahmad Bin Salam, Lacey Dobrolecki, Alaina Lewis, Christina Sallas, Clayton Yates, Carolina Gutierrez, Balasubramanyam Karanam, Meenakshi Anurag, Bora Lim, Matthew Ellis
Publikováno v:
Cancer Research. 82:P2-13
Background.Targeting HER2 gene amplification is one of the great achievements in oncology resulting in the use of a wide array of anti-HER2 agents in the clinic. Unfortunately, 20% of patients still relapse with secondary organ metastasis and are cur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5764a7d6c16c5ad45bef5726ba2749b9
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-24
https://doi.org/10.1158/1538-7445.sabcs21-p2-13-24
Autor:
Suman Mazumder, Taraswi Mitra Ghosh, Ujjal K. Mukherjee, Sayak Chakravarti, Farshad Amiri, Razan S. Waliagha, Farnaz Hemmati, Panagiotis Mistriotis, Salsabil Ahmed, Isra Elhussin, Ahmad-Bin Salam, Windy Dean-Colomb, Clayton Yates, Robert D. Arnold, Amit K. Mitra
Publikováno v:
Cancers; Volume 14; Issue 23; Pages: 6009
Metastatic prostate cancer/PCa is the second leading cause of cancer deaths in US men. Most early-stage PCa are dependent on overexpression of the androgen receptor (AR) and, therefore, androgen deprivation therapies/ADT-sensitive. However, eventual
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86b25f345c41990ec1bd9506640f1f33
https://pubmed.ncbi.nlm.nih.gov/36497496
https://pubmed.ncbi.nlm.nih.gov/36497496
Autor:
Suman Mazumder, Taraswi Mitra Ghosh, Ujjal K. Mukherjee, Sayak Chakravarti, Farshad Amiri, Farnaz Hemmati, Panagiotis Mistriotis, Isra Elhussin, Ahmad-bin Salam, Windy Dean-Colomb, Feng Li, Clayton Yates, Robert D. Arnold, Amit K. Mitra
Metastatic prostate cancer is the second leading cause of cancer deaths in US men. Resistance to standard medical castration and secondary taxane-based chemotherapy is nearly universal. Further, presence of cancer stem-like cells (EMT/epithelial to m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2423b51818457caa5236e5cca42aa714
https://doi.org/10.1101/2022.07.20.500378
https://doi.org/10.1101/2022.07.20.500378
Autor:
Md Shakir Uddin Ahmed, Brittany D. Lord, Benjamin Adu Addai, Sandeep K. Singhal, Kevin Gardner, Ahmad Bin Salam, Anghesom Ghebremedhin, Jason White, Iqbal Mahmud, Rachel Martini, Deepa Bedi, Huixian Lin, Jacqueline D. Jones, Balasubramanyanam Karanam, Windy Dean-Colomb, William Grizzle, Honghe Wang, Melissa Davis, Clayton C. Yates
Publikováno v:
Cancers; Volume 15; Issue 8; Pages: 2282
African American (AA) women with breast cancer are more likely to have higher inflammation and a stronger overall immune response, which correlate with poorer outcomes. In this report, we applied the nanostring immune panel to identify differences in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8da28164a9f10914b92418623ad4bcce
https://doi.org/10.3390/cancers15082282
https://doi.org/10.3390/cancers15082282
Autor:
Rashi Kalra, Ching Hui Chen, Junkai Wang, Ahmad Bin Salam, Lacey E. Dobrolecki, Alaina Lewis, Christina Sallas, Clayton C. Yates, Carolina Gutierrez, Balasubramanyam Karanam, Meenakshi Anurag, Bora Lim, Matthew J. Ellis, Shyam M. Kavuri
Publikováno v:
Cancer research. 82(16)
The pan-HER tyrosine kinase inhibitor (TKI) neratinib is therapeutically active against metastatic breast cancers harboring activating HER2 mutations, but responses are variable and often not durable. Here we demonstrate that recurrent HER2 mutations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b7c89a5c3ad90135eb48dbcc69bf5bd
https://pubmed.ncbi.nlm.nih.gov/35736563
https://pubmed.ncbi.nlm.nih.gov/35736563
Publikováno v:
Nuclear Medicine and Biology. :S40-S41
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88712379f064e64ea5c322c870a63108
https://doi.org/10.1016/s0969-8051(22)00119-6
https://doi.org/10.1016/s0969-8051(22)00119-6